Adaptive Biotechnologies (NASDAQ: ADPT) — Perfil da empresa, notícias e dados financeiros
Adaptive Biotechnologies is a biotech firm focused on precision medicine for diagnosing and treating immune-related diseases.
Adaptive Biotechnologies
Adaptive Biotechnologies (NASDAQ:ADPT) is a biotech firm specializing in the genetics of the adaptive immune system to develop clinical products and services aimed at diagnosing, treating, and managing diseases more precisely. The company leverages its proprietary immune medicine platform to decode the information carried by the immune system, harnessing it for medical diagnosis and treatment, particularly in cancer, autoimmune conditions, and infectious diseases. With a focus on innovative research and development, Adaptive Biotechnologies is committed to advancing the understanding of the immune system’s role in health and disease, aiming to improve patient outcomes through precision medicine. Their projects range from clinical diagnostics to drug discovery, striving to translate the complexity of the immune system into actionable solutions for patients and healthcare providers.
Resumo
Operações
Produtos e/ou serviços de Adaptive Biotechnologies
- T-cell receptor (TCR) sequencing: They sequence and analyze the unique genetic makeup of T-cells, crucial for immune response.
- ClonoSEQ® assay: This proprietary test identifies and characterizes antigen-specific T-cells, aiding in immune monitoring and drug development
- Immune repertoire analysis tools: They provide software and bioinformatics tools to analyze and interpret T-cell receptor sequencing data.
- Discovery and development of immune therapies: They leverage their T-cell expertise to discover and develop novel immunotherapies for cancer and other diseases.
- Collaboration with pharmaceutical and biotechnology companies: They partner with other companies to advance their immunotherapy platforms and drug discovery efforts.
- Clinical trials: They conduct and participate in clinical trials to evaluate the safety and efficacy of their T-cell based therapies.
equipe executiva do Adaptive Biotechnologies
- Chad M. RobinsCo-Founder, CEO & Chairman
- Julie RubinsteinPresident & COO
- Kyle PiskelVP, CFO & Principal Accounting Officer
- Susan BobulskyChief Commercial Officer of MRD
- Christopher CarlsonFounder
- Karina CalzadillaVP of Investor Relations and FP&A
- Clarice McCauleyHead of Legal, Corporate Secretary, VP & Chief Compliance Officer
- Francis T. LoChief People Officer
- Sharon BenzenoChief Commercial Officer of Immune Medicine
- Mary Pat LancelottaSenior Vice President, Global Market & Business Development
Principais indicadores financeiros
Resultados divulgados pela Adaptive Biotechnologies , em USD.
- Cap. de mercado
- 4,5 bi
- Receita (TTM)
- 308,1 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.4
- Dividend yield
- —
- Margem de lucro
- -20.7%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 277 mi | -57,1 mi | -59,5 mi | |
| 179 mi | -162,5 mi | -159,5 mi | |
| 170,3 mi | -227 mi | -225,3 mi | |
| 185,3 mi | -200,2 mi | -200,2 mi |